Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction-Living on the Edge

doi:10.1001/jamacardio.2023.0087

Editorial

. 2023 May 1;8(5):415-416.

doi: 10.1001/jamacardio.2023.0087.

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction-Living on the Edge

Alexander T Sandhu^{1

2}, David J Cohen^{3

4}

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California.
² Department of Medicine, Palo Alto Veteran's Affairs Hospitals, Palo Alto, California.
³ Cardiovascular Research Foundation, New York, New York.
⁴ St Francis Hospital and Heart Center, Roslyn, New York.

PMID: 36870043
PMCID: PMC10175229
DOI: 10.1001/jamacardio.2023.0087

Editorial

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction-Living on the Edge

Alexander T Sandhu et al. JAMA Cardiol. 2023.

. 2023 May 1;8(5):415-416.

doi: 10.1001/jamacardio.2023.0087.

Authors

Alexander T Sandhu^{1

2}, David J Cohen^{3

4}

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California.
² Department of Medicine, Palo Alto Veteran's Affairs Hospitals, Palo Alto, California.
³ Cardiovascular Research Foundation, New York, New York.
⁴ St Francis Hospital and Heart Center, Roslyn, New York.

PMID: 36870043
PMCID: PMC10175229
DOI: 10.1001/jamacardio.2023.0087

No abstract available

PubMed Disclaimer

Comment on

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Cohen LP, Isaza N, Hernandez I, Lewis GD, Ho JE, Fonarow GC, Kazi DS, Bellows BK. Cohen LP, et al. JAMA Cardiol. 2023 May 1;8(5):419-428. doi: 10.1001/jamacardio.2023.0077. JAMA Cardiol. 2023. PMID: 36870047 Free PMC article.

Cited by

Comprehensive Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Reduced Ejection Fraction: A Literature Review.
Lopez-Usina A, Mantilla-Cisneros C, Llerena-Velastegui J. Lopez-Usina A, et al. J Clin Med Res. 2024 Oct;16(10):449-464. doi: 10.14740/jocmr6033. Epub 2024 Oct 11. J Clin Med Res. 2024. PMID: 39544327 Free PMC article. Review.
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes in Heart Failure Patients With Type 2 Diabetes: A Literature Review.
Llerena-Velastegui J, Santamaria-Lasso M, Mejia-Mora M, Granda-Munoz A, Trujillo-Delgado M, Hurtado-Alzate C, de Jesus ACFS, Coelho PM, Baldelomar-Ortiz J. Llerena-Velastegui J, et al. J Clin Med Res. 2024 Sep;16(9):398-410. doi: 10.14740/jocmr5230. Epub 2024 Sep 4. J Clin Med Res. 2024. PMID: 39346567 Free PMC article. Review.
SGLT2 inhibitors: an evidence-based update on cardiovascular implications.
Forzano I, Wilson S, Lombardi A, Jankauskas SS, Kansakar U, Mone P, Varzideh F, Santulli G. Forzano I, et al. Expert Opin Investig Drugs. 2023 Jul-Dec;32(9):839-847. doi: 10.1080/13543784.2023.2263354. Epub 2023 Oct 13. Expert Opin Investig Drugs. 2023. PMID: 37740906 Free PMC article. Review.
Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
Rane A, Nechi RN, Imam M, Zoni CR, Ndikumukiza C, Karaye IM, Yunusa I, Alanzi A. Rane A, et al. J Manag Care Spec Pharm. 2023 Sep;29(9):1045-1053. doi: 10.18553/jmcp.2023.29.9.1045. J Manag Care Spec Pharm. 2023. PMID: 37610112 Free PMC article.

References

1. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. doi:10.1056/NEJMoa2206286 - DOI - PubMed
1. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038 - DOI - PubMed
1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639. doi:10.1161/CIR.0000000000001052 - DOI - PubMed
1. Cohen Laura, et al. Cost-effectiveness of SGLT2 Inhibitors for the Treatment of Heart Failure with Preserved EjectionFraction.
1. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet Lond Engl. 2022;400(10354):757–767. doi:10.1016/S0140-6736(22)01429-5 - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

K23 HL151672/HL/NHLBI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. doi:10.1056/NEJMoa2206286 - DOI - PubMed

[2] Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. doi:10.1056/NEJMoa2206286 - DOI - PubMed

[3] Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038 - DOI - PubMed

[4] Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038 - DOI - PubMed

[5] Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639. doi:10.1161/CIR.0000000000001052 - DOI - PubMed

[6] Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639. doi:10.1161/CIR.0000000000001052 - DOI - PubMed

[7] Cohen Laura, et al. Cost-effectiveness of SGLT2 Inhibitors for the Treatment of Heart Failure with Preserved EjectionFraction.

[8] Cohen Laura, et al. Cost-effectiveness of SGLT2 Inhibitors for the Treatment of Heart Failure with Preserved EjectionFraction.

[9] Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet Lond Engl. 2022;400(10354):757–767. doi:10.1016/S0140-6736(22)01429-5 - DOI - PubMed

[10] Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet Lond Engl. 2022;400(10354):757–767. doi:10.1016/S0140-6736(22)01429-5 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction-Living on the Edge

Affiliations

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction-Living on the Edge

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical